Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Rush University Medical Center, Chicago, IL, United States

Survival: 6.9 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Chicago, IL
Hospital: Rush University Medical Center
Journal: Link
Date: 5/2008

Patients: This phase III study involved 849 patients with non-small-cell lung cancer. The majority of patients (over 70%) were men, and they ranged in age from 30 to 87 years of age.

Treatment: Patients were treated with either paclitaxel poliglumex or docetaxel. These are both chemotherapy drugs.

Toxicities: Grade 3 or 4 neutropenia was reported in 37% of patient treated with docetaxel and 14% of patients treated with paclitaxel poliglumex. Alopecia occurred more often in patients treated with docetaxel, while neuropathy and hypersensitivity reactions were more common in patients receiving paclitaxel poliglumex. No grade 3 or more severe toxicities were reported in patients treated with paclitaxel poliglumex.

Results: The median overall survival was 6.9 months in both treatment groups.

Correspondence: Dr. P. Bonomi

E-mail to a Friend Email Physician More Information